The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background & aims Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications and have higher mortality than other patients with NAFLD. We determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.Methods We performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011. Patients were assigned to mild-, intermediate-, or high-risk groups based on cutoff values for 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score. Outcomes included liver-related complications and death or liver transplantation. We used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios (aHRs).Results During a median follow-up period of 104.8 months (range, 3-317 months), 14% of patients developed liver-related events and 13% died or underwent liver transplantation. The aHRs for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 7.7 (95% confidence interval [CI]: 1.4-42.7) and 34.2 (95% CI: 6.5-180.1), respectively, based on NAFLD fibrosis score; 8.8 (95% CI: 1.1-67.3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2 (95% CI: 1.4-27.2) and 6.6 (95% CI: 1.4-31.1) based on the BARD score. The aHRs for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2 (95% CI: 1.3-13.8) and 9.8 (95% CI: 2.7-35.3), respectively, based on the NAFLD fibrosis scores. Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation (aHR = 3.1; 95% CI: 1.1-8.4 and aHR = 6.6; 95% CI: 2.3-20.4, respectively).Conclusions Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death. NAFLD fibrosis score appears to be the best indicator of patients at risk, based on HRs. The results of this study require external validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Six retrospective cohort studies on individuals with biopsy-proven MASLD showed that NFS and FIB-4 predict the occurrence of liver-related events (AUROCs from 0.72 to 0.86) and overall mortality (AUROCs from 0.67 to 0.82), 176,177 with a similar or lower accuracy compared to histology.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Research works printed but not linked: 1
- Gedaly, 2012, Rising incidence of nonalcoholic steatoheptitis among patients transplanted for hepatocellular carcinoma in the United States, Hepatology, 56, 40A
Cited by
Sorted by citations
Items 401–500 of 501
Mehal, W. Z. (2019) · Gastroenterology & Hepatology International Journal · doi:10.23880/ghij-16000162 · Cited by 4
The Clinical Relevance of Differentiating Nonalcoholic Steatohepatitis From Simple Steatosis
Carter, A., & Mann, J. P. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.10.026 · Cited by 4
Prediction of major liver-related events in the population using prognostic models
Åberg, F. O., & Männistö, V. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf028 · Cited by 3
Shang, Y., Vessby, J., Mangla, K. K., Ota, R., Winther, M. K., Ekstedt, M., & Hagström, H. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2555911 · Cited by 3
Garza, A. L., Lee, M., Blangero, J., Bauer, C., Czerwinski, S. A., & Choh, A. C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.002 · Cited by 3
Armstrong, P. R., Moriarty, A., Dillon, A., Galvin, Z., Russell, J. L., & Stewart, S. F. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003045 · Cited by 3
Liu, H., Cao, Y., Jin, J., Guo, Y., Zhu, C., Wu, N., Hua, Q., Li, Y., Hong, L.-F., Dong, Q., et al. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000033 · Cited by 3
Chen, L.-Z., Jing, X., Chen, X., Xie, Y., Chen, Y., & Cai, X. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2509344 · Cited by 3
Rahadini, A. A. D., & Rahadina, A. (2021) · Bali Medical Journal · doi:10.15562/bmj.v10i2.2359 · Cited by 3
Bouhamou, F., Salihoun, M., Serraj, I., & Kabbaj, N. (2023) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2023.v09i12.004 · Cited by 2
van Beurden, W., Mendoza, Y. P., Lange, N. F., Bosch, J., Berzigotti, A., & Rodrigues, S. G. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108978 · Cited by 2
AST-to-Platelet Ratio Index (APRI) as Marker in Liver Disease
Bakuła, A., & Dądalski, M. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7675-3_2 · Cited by 2
Liu, H.-H., Yen, C., Jeng, W., Hung, C., Hsiao, C.-C., Tian, Y.-C., & Chen, K. (2024) · Diagnostics · doi:10.3390/diagnostics14182048 · Cited by 2
Synergistic impact of serum uric acid and ferritin on MAFLD risk: A comprehensive cohort analysis
Bae, M., Kim, K. M., Jin, M. H., & Yoon, J.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02914-y · Cited by 2
Biochemical Biomarkers of NAFLD/NASH
Celsa, C., Pennisi, G., Spatola, F., Giannetti, A., & Petta, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-37173-9_6 · Cited by 2
Wong, G. L., & Chan, H. L. (2015) · Hepatology International · doi:10.1007/s12072-015-9625-1 · Cited by 2
The Diagnosis of Nonalcoholic Fatty Liver Disease
Kim, M. Y. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.4.405 · Cited by 2
Clinical Aspects of Nonalcoholic Fatty Liver Disease
Mashav, N., & Shibolet, O. (2014) · Oxidative stress and disease · doi:10.1201/b17315-3 · Cited by 2
AST-to-Platelet Ratio Index (APRI) as Marker in Liver Disease
Bakuła, A., & Dądalski, M. (2015) · Exposure and Health · doi:10.1007/978-94-007-7742-2_2-1 · Cited by 2
Jin, Z., Feng, X., Wang, D., Pan, W., Liu, L., Wu, M., Hu, H., Ding, X., Hua, W., Zou, Y., et al. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.101049 · Cited by 2
Noninvasive Assessment of Disease Progression
Tapper, E. B., & Afdhal, N. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00008-2 · Cited by 2
Sebastiani, G., Ghali, P., Deschênes, M., & Wong, P. Y. N. (2015) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2015/943410 · Cited by 2
Non‐Alcoholic Fatty Liver Disease
Hardy, T., & Day, C. P. (2018) · Wiley eBooks · doi:10.1002/9781119237662.ch28 · Cited by 2
Prognostic value of liver fibrosis scores in ambulatory patients with heart failure
Cancelo, A. V., Barge‐Caballero, E., Barge‐Caballero, G., Couto‐Mallón, D., Paniagua-Martin, M. J., Antúnez-Ballesteros, M., Enríquez-Vázquez, D., Grille-Cancela, Z., Muñiz, J., Vázquez‐Rodríguez, J. M., et al. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2468149 · Cited by 1
Madhavi, A. V., & Prasad, S. (2025) · Expert Systems with Applications · doi:10.1016/j.eswa.2025.127711 · Cited by 1
Boeckmans, J., Schattenberg, J. M., Fromme, M., Strnad, P., & Hagström, H. (2025) · Liver International · doi:10.1111/liv.70165 · Cited by 1
Ishiba, H., Sumida, Y., Kamada, Y., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Kawanaka, M., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100668 · Cited by 1
Lu, L., Gao, C., Wu, N., He, S., Liu, Y., Zhang, N., & Zhou, J. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005135 · Cited by 1
Zelber‐Sagi, S., O’Reilly-Shah, V. N., Khanna, A. K., Rock, P., & Bentov, I. (2025) · Anesthesiology · doi:10.1097/aln.0000000000005830 · Cited by 1
Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?
Mittal, S., White, D. L., Kanwal, F., Sussman, N., & El‐Serag, H. B. (2015) · Current Hepatology Reports · doi:10.1007/s11901-015-0259-5 · Cited by 1
Non-Alcoholic Fatty Liver Disease
Alhadyan, R. H. M., Khojah, A. A. Y., & Alanazi, A. G. A. (2018) · The Egyptian Journal of Hospital Medicine · doi:10.12816/0043808 · Cited by 1
Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease
Henry, Z. H., Caldwell, S. H., & Argo, C. K. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0301-2 · Cited by 1
Shiga, T. (2016) · PubMed · Cited by 1
How Can Fatty Liver Lead to Liver Cancer and How Can We Simply Assess It?
Toman, D., Vavra, P., Jelínek, P., Ostruszka, P., Ihnat, P. M., Foltys, A., & Roman, J. H. (2019) · Acta Scientific Gastrointestinal Disorders · doi:10.31080/asgis.2019.02.0100
Bahniy, L., Heryak, S. M., & Bahniy, N. I. (2021) · Acta Scientific Gastrointestinal Disorders · doi:10.31080/asgis.2021.04.0305 · Cited by 1
Waseem, M. A., Saleem, S., Younis, M. Y., Khan, S. H., Jabbar, S., & Ullah, A. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22162914 · Cited by 1
El Hígado graso (parte 2): enfoque clínico y tratamiento
Ortíz, J. E. P., Luque, C. B. S., & Quiróz, R. J. O. (2023) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.979 · Cited by 1
Shen, C., Zhang, J., Tian, Z., Cao, J., Jiao, Y., Wang, B., Feng, S., Luo, Z., Zhang, Q., Deng, Y., et al. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2280-3742 · Cited by 1
Assessing the value of liver fibrosis scores in hypertension: findings from a cross-sectional study
Xiong, S., Li, W., Yin, S., Deng, W., Zhao, Y., Wang, P., Guo, X., Sun, Y., & Yang, H. (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000104 · Cited by 1
Wahiduzzaman, M., Ferdous, N.-E., Haque, K. M. M., Kabir, A. K. M. S., Siddiki, M. A., Hossain, M., Rahman, Q. A., Rahman, A., & Kibria, A. H. M. G. (2024) · Cureus · doi:10.7759/cureus.76162 · Cited by 1
Surrogate Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC)
(2017) · Internal Medicine Research – Open Journal · doi:10.31038/imroj.2017231 · Cited by 1
Monitoring of hepatic fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00012-3 · Cited by 1
Editorial: A New Spin on Magnetic Resonance Elastography
Kishore, R., Loomba, R. S., & Sterling, R. K. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.134 · Cited by 1
Metabolic Syndrome and Non‐alcoholic Fatty Liver Disease
Angulo, P. (2016) · doi:10.1002/9781119127437.ch83 · Cited by 1
FIB-4 First in Diagnostic Algorithm of MAFLD at the Era of “Global Metabodemic “Preprint
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · Preprints.org · doi:10.20944/preprints202008.0417.v1 · Cited by 1
Vincentis, A. D., Incalzi, R. A., Picardi, A., & Gentilucci, U. V. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107891 · Cited by 1
Sun, L., Jia, H., Lei, L., Huang, D., & Yang, T. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16774 · Cited by 1
En memoria del Dr. Paul Angulo (20 de abril de 1965 - 25 de febrero de 2015)
Montaño‐Loza, A. J. (2015) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2015.08.001
Méndez‐Sánchez, N. (2015) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31287-6
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Alkhouri, N., Mansoor, S., Giammaria, P., López, R., & Nobili, V. (2014) · Gastroenterology · doi:10.1016/s0016-5085(14)60040-8
Hígado graso no alcohólico. Papel de los médicos de atención primaria
Caballería, J., & Caballería, L. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.04.012
Festi, D., Schiumerini, R., Marasco, G., Scaioli, E., Pasqui, F., & Colecchia, A. (2015)
In Memory of Dr. Paul Angulo (April 20, 1965 - February 25, 2015)
Montaño‐Loza, A. J. (2015) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2015.08.008
Nonalcoholic Fatty Liver Disease: What's the Long-Term Prognosis?
Zaman, A. (2013) · Journal watch · doi:10.1056/nejm-jw.na32473
Non-alcoholic fatty liver disease. Role of primary care physicians
Caballería, J., & Caballería, L. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.01.002
Nonalcoholic Fatty Liver Disease (NAFLD) after Liver Transplantation: A Mini-Review
de Oliveira, C. P. M. S., & Álvares‐da‐Silva, M. R. (2015) · Journal of Liver Disease & Transplantation · doi:10.4172/2325-9612.1000127
How to best diagnose NAFLD/NASH?
Ratziu, V. (2016) · doi:10.1002/9781118924938.ch13
The clinical utility of noninvasive blood tests and elastography
Tsochatzis, E. A., & Pinzani, M. (2016) · doi:10.1002/9781118924938.ch14
THE EFFECT OF HAART ON LIVER DISEASE PROGRESSION IN HIV INFECTION
Price, J. C. (2015)
Wong, R. J., Tran, T. T., Kaufman, H. W., Niles, J. K., & Gish, R. G. (2020) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2020.03.002
Hepatic steatosis, steatohepatitis, and chemotherapy-related liver injury
Reddy, S. K., & Geller, D. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00071-6
Riou, J., Canivet, C. M., & Boursier, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.020
ERKRANKUNGEN DER VERDAUUNGSORGANE
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50008-5
Neue diagnostische Methoden für Patienten mit Diabetes und Fettleber
Schattenberg, J. M., & Geier, A. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00648-1
Non-invasive Diagnostic Approach to NASH: Biological Markers
Petta, S., & Giannetti, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_13
Diagnostic Assessment of Nonalcoholic Fatty Liver Disease
Jin, Y. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.5.299
Yonemura, Y., Yoshizumi, T., Tomiyama, T., Iseda, N., Morinaga, A., Yugawa, K., Harada, N., Takeishi, K., Toshima, T., Nagao, Y., et al. (2020) · International Surgery · doi:10.9738/intsurg-d-20-00034.1
Bahniy, L., Heryak, S. M., & Bahniy, N. I. (2021) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2020.2.11835
Маршалко, Д. В., Pchelin, I. Y., & Шишкин, А. Н. (2018) · Juvenis scientia
Mathurin, P., Dharancy, S., & Lassailly, G. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76753-1.00050-3
An algorithm for the management of non-alcoholic fatty liver disease in primary care
Dinani, A. M., Sussman, N., Noureddin, M., Fuchs, M. A., Therapondos, G., Girgrah, N., Diaz, V. F., Mantry, P., Rinella, M. E., Asgharpour, A., et al. (2021) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2021.12.00469
Coutinho, A., Reddy, N., & Khan, M. I. (2021) · International Journal of Dentistry Research · doi:10.31254/dentistry.2021.6306
Weiß, J., Rau, M., & Geier, A. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0144
Cianci, N., Subhani, M., Hill, T., Khanna, A., Zheng, D., Sheth, A., Crooks, C. J., & Aithal, G. P. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i5.1026
Geier, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_15
Ku, G. D. L. C., Zevallos, A., Rázuri-Bustamante, C. R., Kalipatnapu, S., Príncipe-Meneses, F. S., Dongo, P., Chambergo‐Michilot, D., Salinas-Sedo, G., & Valcarcel-Valdivia, B. (2023) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2022.0043
Livzan, M. A., Сергеевна, К. Т., & Syrovenko, M. I. S. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-212-4-133-139
NONALCOHOLIC FATTY LIVER DISEASE AND ALBUMINURIA : A SYSTEMATIC REVIEW
Taufika, A. R., & Niamullah, A. (2023) · Journal of Advance Research in Medical & Health Science · doi:10.53555/gvhtv709
Can the FIB-4 score predict the severity of acute pancreatitis in NAFLD?
Kırdok, K., Yogurtcu, Ö., Buran, T., & Kasap, E. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-024-00313-y
Kunt, Ç., Kollu, K., Kunt, F. B. Ç., Ünal, B. C., Güngör, G., Kızılarslanoğlu, M. C., & Güney, İ. (2024) · Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi · doi:10.47572/muskutd.1429164
Wadhawan, M. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250286
Kamada, Y., Sumida, Y., Takahashi, H., Fujii, H., Kawanaka, M., Nakajima, A., & Forum, J. (2025) · Kanzo · doi:10.2957/kanzo.66.105
Pozzobon, F. M., Luiz, R. R., Parente, J. G., Guarilha, T. M., Fontes, M. P. R. C., Chindamo, M. C., & Perez, R. D. M. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002966
Garza, A. L., Blangero, J., Lee, M., Bauer, C., Czerwinski, S. A., & Choh, A. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104812
Metabolic disorders associated with liver dysfunction
Akash, M. S. H., & Rehman, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36312-2.00007-3
Brekhunets, R. M., Андреев, Д. Н., Maev, I. V., Dicheva, D. T., & Киримовна, К. А. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-225
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
Dai, H., Xiang, J., Hou, Y., Xuan, L., Wang, T., Li, M., Zhao, Z., Xu, Y., Lu, J., Chen, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14068002
Peng, J., Liu, M.-M., Jin, J.-L., Yexuan, C., Yuanlin, G., Wu, N.-Q., Zhu, C.-G., Dong, Q., Sun, J., Xu, R.-X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.18070945
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.27012178
Lopez, C., Finer, Z. R., Sharpton, S. R., Lister, R., Thompson, J. L., Lindsell, C. J., Gao, Y., DUCKHAM, H. E., & Izzy, M. J. (2026) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002322
Marqueurs non-invasifs de stéatose et fibrose hépatique
Perazzo, H. (2014) · theses.fr (ABES) · doi:10.70675/02aba680z77b0z4903z96b9zce1c22dcaa83
Alcântara, R. W. A., Oliveira, V. M. R., Samad, N. S., Barbosa, L., Barroso, W. K. S., Nadruz, W., Maranhão, R. C., Nascimento, B. R., Amat-Santos, I. J., & Moreira, H. G. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103350
Wang, X. W., Dong, X., 钱洛丹, Yang, Z., Yang, D., & Niu, Y. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.06.068
McGoogan, K. E., Hegde, V. K., Wilburn, J., Cooper, F. I., Gurnurkar, S., do Prado, W. L., & Balagopal, P. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02101-7
Bozkürk, M. B., Coşkun, Y., Kul, G., GÜÇEL, F., Us, R. B., Çelik, M. T., Öztürk, A., & Tütüncü, E. E. (2026) · Online Türk Sağlık Bilimleri Dergisi · doi:10.26453/otjhs.1823481
Metadata
- Authors
- Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Turin (IT)
- National University Hospital of Iceland (IS)
- Siriraj Hospital (TH)
- Gartnavel General Hospital (GB)
- Newcastle University (GB)
- The University of Sydney (AU)
- Corresponding author
- Angulo, Paul
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 145
- Issue
- 4
- Pages
- 782-789.e4
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3931256
- OpenAlex
- W2129639561
- Cited by
- 502
- References
- 32
- Citations by year
- 2026: 7 · 2025: 29 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 60 · 2020: 49 · 2019: 40 · 2018: 39 · 2017: 35 · 2016: 36 · 2015: 49 · 2014: 45 · 2013: 4
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (R01 DK82426)
- Seventh Framework Programme (HEALTH-F2-2009-241762)
- National Health and Medical Research Council (1049857, 632630)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, NAFLD fibrosis score, FIB-4, BARD score, liver complications, mortality, liver transplantation, disease progression, prognosis, liver fibrosis, risk stratification, prognostic accuracy
- MeSH terms
- Adult, Fatty Liver, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Cohort Studies, Kaplan-Meier Estimate, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
